<DOC>
	<DOCNO>NCT02004860</DOCNO>
	<brief_summary>Seborrheic dermatitis chronic inflammatory dermatological disease , evolve relapse , affect mainly face scalp . It would important maintenance treatment severe form seborrheic dermatitis witch effective relatively well tolerate reduce frequency relapse , prolong remission obtain attack treatment reduce use topical steroid .</brief_summary>
	<brief_title>Tacrolimus Ointment Interest ( PROTOPIC ® ) Maintenance Treatment Severe Seborrheic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Seborrheic</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Ciclopirox</mesh_term>
	<criteria>Phase 1 : Attack Treatment ( open ) 1. age eighteen patient , 2 . Seborrheic dermatitis Severe , 3. participation inform consent , 4 . Women childbearing age effective contraception duration study postmenopausal woman . Phase 2 : Phase 2 : `` Randomization '' ( blind ) 1 . Patient achieve complete almost complete clinical remission initial treatment , 2. know immunodeficiency ( HIV patient receive chemotherapy ) immunosuppressive therapy biotherapy , 3. patient take regular systemic corticosteroid dose &gt; 20 mg / day 4. erythematous lesion topography face evocative scalp psoriasis ( elbow , knee ... ) , refer possibility facial lesion correspond lesion sebopsoriasis , 5. woman pregnant , nurse childbearing potential without effective contraception , 6. man wish child study period , 7 . Ultra Violet ( UV ) phototherapy usual realization UV session aesthetic purpose , 8 . Seborrheic dermatitis symptomatic underlying disease know reveal 9. history cancer lymphoma , 10. progressive cancer lymphoma , 11 . Seborrheic dermatitis exclusively affect scalp , 12. know allergy onecomponent product study , 13. malnourish patient sick history chronic pancreatitis suspect deficiency dermatitis , 14. participation clinical trial Seborrheic dermatitis previous 90 day , 15. patient lesion consider potentially malignant precancerous , 16. patient abnormal skin barrier . Phase 1 : Attack Treatment ( open ) 1 ) Patient already treat Protopic ® Seborrheic Dermatitis , Phase 2 : `` Randomization '' ( blind ) 1 ) Patient complete almost complete clinical remission initial treatment ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>local immunosuppressive</keyword>
	<keyword>Maintenance therapy</keyword>
</DOC>